Forsta AP Fonden reduced its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 6.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 412,762 shares of the company’s stock after selling 29,800 shares during the period. AbbVie makes up about 0.6% of Forsta AP Fonden’s holdings, making the stock its 22nd largest holding. Forsta AP Fonden’s holdings in AbbVie were worth $70,797,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also modified their holdings of the company. Ridgewood Investments LLC acquired a new stake in AbbVie in the second quarter valued at $27,000. Vermillion & White Wealth Management Group LLC acquired a new stake in AbbVie in the fourth quarter valued at $26,000. IFS Advisors LLC acquired a new stake in AbbVie in the first quarter valued at $36,000. Redmont Wealth Advisors LLC acquired a new stake in AbbVie in the first quarter valued at $37,000. Finally, Quest Partners LLC raised its stake in AbbVie by 4,140.0% in the second quarter. Quest Partners LLC now owns 212 shares of the company’s stock valued at $36,000 after buying an additional 207 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, Chairman Richard A. Gonzalez sold 66,500 shares of AbbVie stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $186.52, for a total transaction of $12,403,580.00. Following the completion of the transaction, the chairman now directly owns 446,599 shares in the company, valued at approximately $83,299,645.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Chairman Richard A. Gonzalez sold 282,845 shares of the business’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $175.00, for a total transaction of $49,497,875.00. Following the completion of the sale, the chairman now directly owns 513,099 shares of the company’s stock, valued at approximately $89,792,325. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Richard A. Gonzalez sold 66,500 shares of the business’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $186.52, for a total transaction of $12,403,580.00. Following the sale, the chairman now directly owns 446,599 shares of the company’s stock, valued at $83,299,645.48. The disclosure for this sale can be found here. Insiders own 0.25% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Stock Analysis on AbbVie
AbbVie Price Performance
Shares of NYSE:ABBV opened at $194.59 on Thursday. The company has a quick ratio of 0.71, a current ratio of 0.81 and a debt-to-equity ratio of 8.51. The company has a market cap of $343.62 billion, a P/E ratio of 57.74, a PEG ratio of 2.64 and a beta of 0.64. AbbVie Inc. has a 52 week low of $135.85 and a 52 week high of $199.95. The company has a 50-day moving average price of $185.68 and a 200 day moving average price of $175.02.
AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings results on Thursday, July 25th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.08. AbbVie had a net margin of 9.71% and a return on equity of 203.66%. The company had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.02 billion. During the same period last year, the firm earned $2.91 EPS. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. Research analysts predict that AbbVie Inc. will post 10.86 earnings per share for the current year.
AbbVie Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be given a dividend of $1.55 per share. The ex-dividend date of this dividend is Tuesday, October 15th. This represents a $6.20 annualized dividend and a dividend yield of 3.19%. AbbVie’s dividend payout ratio is currently 183.98%.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Featured Stories
- Five stocks we like better than AbbVie
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- Business Services Stocks Investing
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- Investing in Travel Stocks Benefits
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.